Impact of partial reimbursement on hepatitis B antiviral utilization and adherence

Figure 1 Antiviral agent utilization before and after reimbursement for patients with different characteristics. A: Antiviral agent utilization before and after reimbursement for patients with different insurance types; B: Utilization of different NAs for PMI vs PPO before and after reimbursement C1: Utilization of specific antiviral among new and existing PMI before reimbursement; C2: Utilization of specific antiviral among new and existing PMI after reimbursement; C3: Utilization of specific antiviral among new and existing PPO before reimbursement; C4: Utilization of specific antiviral among new and existing PPO after reimbursement. ^aP < 0.05, ^bP < 0.01, before reimbursement vs after reimbursement. PMI: Patients with medical insurance; PPO: Patients paid out-of-pocket.

Figure 2 Persistence rate before and after reimbursement for patients with different characteristics. A: Persistence rate before and after reimbursement for patients with different insurance types; B1: Persistence rate for new patients with different insurance types; B2: Persistence rate for existing patients with different insurance types. PMI: Patients with medical insurance; PPO: Patients who paid out-of-pocket.